PORPP

Pharmaceutical Outcomes Research & Policy Program

Annual Report 2012

Congratulations to the June 2012 PORPP Graduates

On the Cover (L to R); Veena Shankaran, MD, MS; Heidi Wirtz, MS, PharmD, PhD; Rafael Alfonso,

MD, MS, PhD; Joanna Sanderson, PharmD, MS; Jonathan Watanabe, PharmD, MS, PhD; Ryan Hansen,

PharmD, PhD; Cara McDermott, PharmD, MS; Joshua Roth, MHA, PhD

2 PORPP

PORPP Faculty

Joseph Babigumira, MBChB, MS,

PhD

Adjunct Assistant Professor

Denise Boudreau, PhD

Affiliate Associate Professor

Brian Bresnahan, PhD Adjunct Research Assistant Professor

Josh Carlson, MPH, PhD

Research Assistant Professor

Emily Beth Devine, PharmD, MBA,

PhD, Associate Professor

David Flum, MD, MPH

Adjunct Professor

Louis Garrison, Jr., PhD Professor, Associate Director

Bernardo Goulart, MD, MS

Adjunct Assistant Professor

Shelly Gray, PharmD, MS,

Professor

Thomas Hazlet, PharmD, DrPH

Associate Professor

Jerry Jarvik, MD, MPH

Adjunct Professor

Larry Kessler, ScD, Professor and

Chair, Dept. of Health Services

Donald Patrick, PhD Adjunct Professor

Scott Ramsey, MD, PhD, Adjunct

Professor, Director, I-CORE (Institute

for Cancer Outcomes Research and Evaluation), Fred Hutchinson

Cancer Research Center

Andy Stergachis, PhD Adjunct Professor

Sean Sullivan, PhD, Stergachis Family

Endowed Professor and Director,

PORPP

David Veenstra, PharmD, PhD

Professor, Director, Graduate Programs

Staff

Penny Evans

Graduate Program Advisor Laurie Gold, PhD

Paul Kraegel, MSW

Pharmaceutical Outcomes Research

and Policy Program Department of Pharmacy,

University of Washington

Box 357630, Seattle, WA 98195-7630 Phone: 206-616-1383,

Fax: 206-543-3835

Email: pennye@uw.edu http://sop.washington.edu/porpp

August 30, 2012

MESSAGE FROM THE DIRECTOR

I am pleased to provide you with the annual report of

the University of Washington Pharmaceutical Out-

comes Research and Policy Program (PORPP), cata-

loging the activities, scholarship and professional

accomplishments of the faculty, staff, graduate stu-

dents and post-doctoral fellows. As you will see

while turning the pages of this report, these dedicated

and hard-working individuals have made substantial

achievements in their respective disciplines, too nu-

merous to list in this brief introduction. PORPP is

extremely fortunate to have scientists, students and

staff of the highest caliber.

I would, however, like to highlight a few of the more notable activities of the Pro-

gram in the past year.

This month, we welcome our first class of Distance Learning students enrolled

in the Certificate in Health Economics and Outcomes Research. A total of forty

students will complete 3 courses over a 9-month period, all from the comfort of

their own computer. The students come from a variety of backgrounds, job set-

tings and geographies.

With funding from the PhRMA Foundation, Drs. Basu, Devine and Garrison

have launched a health sciences-wide graduate certificate in Comparative Effec-

tiveness Research intended to strengthen the didactic curriculum in CER meth-

ods for students in the PORPP and Health Services PhD programs.

This past month we were notified that our application to join the AHRQ-funded

Evidence-based Practice Center network was successful. We have joined

OHSU and Spectrum Research as partners and will be named the Pacific North-

west Evidence-Based Practice Center.

Our faculty and alumni have been generous in support of the program this year. Last

April, Dr. and Mrs. Andy Stergachis donated funds to establish the Stergachis Fam-

ily Professorship and Director of PORPP. I am honored to be named the first recipi-

ent, but readily acknowledge that this endowment creates an enduring legacy for the

PORPP program. In addition, I will soon announce the Higashi Family Endowed

Fund. Mitch and Mandy Higashi have generously donated to establish a graduate

and post-doctoral fellow travel fund within the PORPP program.

This year, we have admitted one of the largest and most diverse graduate classes.

Drs. Veenstra, Devine and Hazlet managed to recruit all of our top candidates to the

Program. Each of the students is profiled in this newsletter. Finally, I would like to

acknowledge the dedicated support from our program and research coordinators,

Penny Evans and Paul Kraegel, who have played a major role in the accomplish-

ments that you see throughout these pages.

Table of Contents Graduating Class & New Students……………………………………………………….3

Current Students………………………………………………………………………….4

Recent Graduates in the Workforce……………………………………………………..6

Post-Docs…………………………………………………………………………………7

Endowed Directorship, PORPP Prize, David Blough……………………......................8

Scott Ramsey, ICORE, Certificate Programs…………………………………………...9

Student Publications……………………………………………………………………..9

Post-Doc Publications………………………………………………………………….10

Faculty Publications……………………………………………………………………11

Faculty Grants………………………………………………………………………….13

Gift Acknowledgements………………………………………………………………..14

Graduating Class of 2012

Master of Science in Pharmacy Degrees

Cara McDermott, AB 1999, Princeton University;

PharmD 2011, University of Washington; MS 2012 Uni-

versity of Washington

Thesis: “The Impact of Adherence and an Intervention

Program on Patient Outcomes and Costs in Chronic Hepa-

titis C Infection”

Chair: Sean Sullivan, PhD

Joanna Sanderson, BA 2005, Western State College of

Colorado; PharmD 2011, University of Washington; MS

2012, University of Washington

Thesis: “Migraine-Specific Health Resource Utilization in

Chronic and Episodic Migraine Across Six Countries”

Chair: Sean Sullivan, PhD

Veena Shankaran, BA 1998, Dartmouth College; MD

2002, University of Michigan; MS 2012, University of

Washington

Thesis: “Adverse Events Associated with Bevacizumab

and Chemotherapy in Older Patients with Metastatic Colo-

rectal Cancer”

Chair: Scott Ramsey, MD, PhD

Doctor of Philosophy in Pharmacy Degrees

Rafael Alfonso Cristancho, MD 1999, Universidad del

Rosario; M.Sc. 2005, Universidad Autonoma de Barce-

lona; PhD 2012, University of Washington

Dissertation Title: “Bariatric Surgery: Determinants of Use

and Economic Impact”

Chair: Sean Sullivan, PhD

Ryan N. Hansen, BA 1999, Carroll College; PharmD

2003; PhD 2012, University of Washington

Dissertation Title: “The Association Between Sedative

Hypnotic Insomnia Treatments and Motor Vehicle

Crashes”

Chair: Sean Sullivan, PhD

Joshua A. Roth, BS 2004, Union College; MHA 2008

University of Washington; PhD 2012, University of

Washington

Dissertation Title: “Comparative Effectiveness Ap-

proaches to Evaluate Pharmacogenomic Technology”

Chair: David Veenstra, PharmD, PhD

Jonathan H. Watanabe, BS 1998, University of Wash-

ington; PharmD 2007, University of Southern California;

MS 2008, University of Washington; PhD 2012, Univer-

sity of Washington

Dissertation Title: “Evaluation of a Medicaid Drug Policy

to Improve Health System Efficiency Through Modifica-

tion of Provider Prescribing Behavior”

Chair: Sean Sullivan, PhD

Heidi S. Wirtz, BS 1994, University of Iowa; MS 1996

University of Iowa; PharmD 2000, Creighton University;

PhD 2012, University of Washington

Dissertation Title: “Second Breast Cancer Events in Rela-

tion to Frequent Antibiotic Use: An Assessment of Risk

and the Development of a Framework to Evaluate Detec-

tion Bias in Breast Cancer Pharmacoepidemiology Stud-

ies”

Chair: Denise Boudreau, PhD

Welcome Our New Students

William Canestaro, MS

Will is coming to PORPP having just finished working

three years for Generation Health (GH) where he left as an

Assistant Director of Clinical Research. His responsibili-

ties at GH included economic modeling and health tech-

nology assessments of emerging molecular diagnostics.

His work helped secure strategic funding from CVS Care-

mark who eventually became a majority owner and imple-

mented a pharmacogenomic testing outreach program in

their population. As part of his role in the research division

of GH, he helped build a strategic relationship with Har-

vard University and Brigham and Women's Hospital Divi-

sion of Pharmacoepidemiology and has several research

projects underway including a cost-effectiveness analysis

of novel oral anticoagulants as well as a clinical effective-

ness evaluation of the GH testing outreach program. Prior

to joining GH, Will completed a Master's in Medical An-

thropology at Oxford University and his undergraduate

studies at Dartmouth College where he was selected for a

competitive post-graduate fellowship. Will is moving to

Seattle with his wife Sarah, and his two children and is

extremely excited to learn from all of the faculty at UW.

Sara Forrester, PharmD

Sara received her PharmD from the University of Wash-

ington in 2012. She currently works at The Everett Clinic

focusing on Medicare reimbursement and clinical quality

measures in their diabetes patient population. Working at

The Everett Clinic and the Health Care Authority of Wash-

ington, Sara developed a passion for understanding and

utilizing health economics to make decisions that improve

the health of populations. She looks forward to joining

PORPP and working with their renowned faculty to im-

prove her analytic and research skills, particularly in the

field of diabetes.

Carlos Gallego, MD

Carlos is a recently graduated Internist Geneticist from the

University of Alabama at Birmingham. He is one of the

first graduates of the combined Internal Medicine/Medical

Genetics program in the country. He is looking forward to

studying the effect of genetic testing in health outcomes

and how genetic research affects health care technology

implementation. PORPP will provide him with the tools

necessary to expand his career in an academic environ-

ment.

Zsolt Hepp, PharmD

Zsolt is one of the current Allergan fellows. He com-

pleted his PharmD degree this year at the University

of Washington. Zsolt is currently working with Beth De-

vine on a cost effectiveness model comparing the new

electronic physician order entry system to the standard

written prescription system at The Everett Clinic. He has

been interested in outcomes research since competing in

the AMCP P&T competition in his second year of

Fall 2012 3

4 PORPP

pharmacy school. That interest grew while completing

numerous rotations during his fourth year including one

with the outcomes research group at Allergan. He is look-

ing forward to learning more about economic modeling

and various other skills within outcomes research.

Nita Khandelwal, MD

Nita is on faculty at UW in the Department of Anesthesiol-

ogy. She divides her clinical time between the Trauma

ICU, Neurosurgical ICU and operating rooms at Harbor-

view Medical Center. She is beginning her 2nd year in the

PORPP program. Her focus and research interests involve

comparative effectiveness and cost effectiveness research

related to critical care. Her career goal is to improve the

quality of care and the quality of life of ICU patients by

evaluating and implementing strategies that could lead to

optimization of outcomes and cost minimizations. She is

currently involved in a study that is examining reasons for

extubation failure and development and implementation of

an algorithm to reduce re-intubation rates.

Solomon Lubinga, BPharm, MSc

Solomon completed his Pharmacy degree from Makerere

University, Uganda in 2003. In 2007, he received a Com-

monwealth Scholarship and spent 1 year at the University

of Strathclyde in the UK, obtaining a distinction Master of

Science degree in Clinical Pharmacy. He has served as a

Clinical Lecturer and Pharmacist at the Department of

Pharmacy of Mbarara University of Science and Technol-

ogy and its teaching hospital, Mbarara Regional Referral

Hospital located in rural Western Uganda. Through the

PORPP program, Solomon hopes to acquire theoretical

knowledge in epidemiology, economics, biostatistics and

health services research, and to develop as an independent

researcher and health professions educator. He hopes to

use the knowledge acquired to guide health policy deci-

sions and to improve access to quality and cost-effective

essential medicines and health supplies in low-income

countries. He also hopes to use his training to train other

Outcomes Research scientists in developing countries.

Marita Mann, BS, MPH

Marita’s undergraduate degree in chemical and biomedical

engineering led her to a career in the pharmaceutical in-

dustry. After working in the field both domestically and

internationally, she decided to change career paths and left

industry to pursue her MPH at Brown University. During

that time she worked on and authored papers in the areas

of HIV drug resistance in Kenya, opioid abuse, and Pre-

scription Monitoring Programs. At the UW she intends to

combine her interest in pharmacoepi and global health.

Marita is excited to join PORPP and hopes to utilize the

knowledge she gains to research optimization of drug use

and distribution in resource-limited settings.

Maria Agapova, MPH

Maria completed her second year and required program

coursework and is looking forward to devoting her time to

refining her short proposal topic. Maria is interested in the

costs and outcomes of antipsychotic pharmacotherapy in

the population diagnosed with autism. This past year she

presented her work in modeling long term costs of two

competing cervical cancer screening strategies for the

country of Ireland at the European Society for Decision

Making in Oslo, Norway, and at the Meeting in the Middle

in Austin, Texas. Under the mentorship of Dr. Devine,

Maria is working on an educational manuscript comparing

the Frequentist and Bayesian methods for pooling data

across clinical trials of asthma educational interventions.

She enters her third year at PORPP as the Comparative

Effectiveness Research fellow and also has been awarded

the GE Healthcare pre-doctoral fellowship.

Preeti Bajaj, BS

Preeti has completed her third year in the PORPP program

and is currently defining her dissertation research. She

hopes to continue pursuing her research interests in phar-

macoeconomics, policy and R&D efficiency. This past

year, after returning from an internship with Novartis

Pharmaceuticals in Basel, she conducted research with Lou

Garrison on the mechanisms for rewarding innovation in

value-based pricing schemes. She has recently presented

her research at the Society for Medical Decision Making

Annual Meeting and the Western Pharmacoeconomics

Conference Meeting in the Middle.

Caroline Bennette, MPH

Carrie is entering her second year as a PhD student in

PORPP, having spent her first year working closely with

David Veenstra on the development of a patient reported

outcome measure. This instrument will be used as part of

a randomized controlled trial of whole exome sequencing

to measure the psychological impact of this new type of

genetic testing in patients with colon cancer. This sum-

mer, Carrie began working on a cost-effectiveness model

of whole exome sequencing and exploring potential disser-

tation topics.

Current Students Research & Projects

Chris Wallick, PharmD

Chris is one of the current Allergan fellows. He completed

his PharmD at the University of Washington in 2011. He is

currently studying adherence and persistence in glaucoma

and diabetic macular edema. Chris has had a prior interest

in research, publishing eight papers while working in a

molecular biology lab at the Cancer Research Center of

Hawaii. He was drawn to outcomes research after a clini-

cal rotation with the WHO in Australia during his final

year rotations. Chris is greatly looking forward to learning

more about outcomes research and finding a focused area

for his thesis project.

Amy Cizik, MPH

Amy finished her first year in the PhD program. She con-

tinues to work part-time as a research scientist in the De-

partment of Orthopaedics and Sports Medicine and co-

authored several manuscripts in the field of surgical out-

comes following spine and other orthopaedic-related pro-

cedures. Her first author work, published in the Journal of

Bone and Joint Surgery is entitled, "Using the spine surgi-

cal invasiveness index to identify risk of surgical site in-

fection: a multivariate analysis". Since beginning PORPP

Amy has developed an interest in orthopaedic device use

in a global health context and was successful in obtaining

funding from the Thomas Francis, Jr. Global Health Travel

Fellowship. Amy traveled to Dar Es Salaam, Tanzania

where she conducted a study evaluating the use of Open

Data Kit, a mobile phone application, developed in the

Department of Computer Science and Engineering.

There she collected data for a surgical database that tracks

the use of an orthopaedic device, the SIGN nail, for femur

fractures. She hopes to use this work as a foundation for

her dissertation.

Katie Gries, PharmD, MS

Katie successfully passed the general exam for her disser-

tation project titled Influence of Perspective on Prefer-

ences for Prostate Cancer. Katie contributed to work that

was presented as a poster at the ISPOR conference in

Washington DC: “Psychiatrists’ Preferences for Attributes

of Antipsychotic Medications to Treat Schizophrenia: A

Conjoint Analysis”. Katie’s qualitative work in idiopathic

pulmonary fibrosis will be presented as a poster at the IS-

POR European Congress in November 2012: “Content

Validity of Two Symptom Questionnaires for Idiopathic

Pulmonary Fibrosis”.

Richard Kim, MD

Richard Kim will be entering his second year in PORPP.

He anticipates completing his Masters degree this year and

advancing to the PhD program. In the past year, he com-

pleted a cost minimization analysis of the HomePAP™

trial, a large multi-center randomized controlled trial com-

paring home-based diagnosis of obstructive sleep apnea

versus the standard laboratory-based testing pathway. He

also has several projects in lung cancer currently under-

way, including an analysis of regional data for the effect

that visiting a pulmonologist has on lung cancer outcomes.

He presented some of his data at the ISPOR meeting this

past year.

Cara McDermott, PharmD, MS

This year Cara completed her Master's degree and the the-

sis title is "The impact of adherence and an intervention

program on patient outcomes and costs in chronic hepatitis

C infection." She has worked on a modeling project while

working as a TA in the PharmD program. As a Huckabay

fellow, she designed and delivered a learning module on

end of life care for PharmD students, and she has submit-

ted an abstract to the American College of Clinical Phar-

macy.

Current Students—Research & Projects

Cara is the lead author on two publications in the past year,

"Advising Patients with Breast Cancer Regarding Aroma-

tase Inhibitors - Dietary Supplement Interactions" and

"Cholinesterase Inhibitor Adjunctive Therapy for Cogni-

tive Impairment and Depressive Symptoms in Older

Adults with Depression." Cara will continue on in the PhD

program this fall.

Norio Kasahara, MPH

Norio will be working on his dissertation research over the

summer titled "Assessing the Quality and Price of Medi-

cines in Afghanistan: Improving Pharmaceutical Services

in a Fragile State". His General Examination is scheduled

for Autumn 2012. Along with the dissertation, he will be

engaged in the health systems development project funded

by the European Union in Afghanistan until 2014.

Hiep Nguyen, MPH

Hiep is entering his fourth year of the PhD program. He

has spent this past year working with Lou Garrison and

Andy Stergachis on a landscape assessment of health tech-

nology assessment (HTA) in selected low– and middle-

income countries. Hiep contributed to the study by review-

ing the published and grey literature and preparing a report

on Vietnam’s health system and HTA activities. Hiep was

also an author in a poster that was presented at this year’s

ISPOR 17th Annual International Meeting, entitled

“Developing and implementing patient-resource use dia-

ries for a clinical trial assessing spinal stenosis interven-

tions in the elderly.” He is in the process of identifying a

dissertation topic in the area of global health.

Joshua Roth, MS

Josh has been working on completing his dissertation, ti-

tled “Comparative Effectiveness Approaches to Evaluate

Pharmacogenomic Technology”. In doing so, he has im-

plemented a case-control study to evaluate the association

between genetic variants and major bleeding in warfarin

therapy, conducted a value of information analysis to as-

sess the value of future research for ERCC1 testing in

Stage I non-small cell lung cancer, and has completed a

policy analysis about the application of benefit-risk model-

ing to inform regulatory decisions about genomic tests.

Additionally, Josh was a co-author on a meta-analysis of

adjuvant chemotherapy decisions in early-stage breast can-

cer patients following Oncotype Dx testing that was pre-

sented at the American Society for Clinical Oncology

meeting in June. Josh is defending his dissertation in Au-

gust, and plans to start a post-doctoral fellowship at Fred

Hutchinson Cancer Research Center after graduation.

Joanna Sanderson, PharmD, MS

Joanna Sanderson is now in the second year of the PORPP

-Allergan fellowship and will spend this coming year on

the Allergan campus in Irvine, CA. Over the past year,

Joanna completed her master’s degree in the program, with

her thesis entitled: “Migraine-specific health resource utili-

zation in chronic and episodic migraine across six coun-

tries.” She also worked on several other projects during the

Fall 2012 5

Recent Graduates in the Workforce

Rafael Alfonso, MD, PhD As of July 1st, Rafael is officially a Research Assistant Professor in the UWMC Department of Surgery in the School of Medi-cine. He will work primarily at the Surgical Outcomes Research Center (SORCE) as the Scientific Director under Dave Flum. He is currently working as the scientific liaison in the projects of the Comparative Effectiveness Research Translation Net-work (CERTAIN). Rafael is also actively participating and creating research proposals in CER and Patient‐Centered Outcomes Research for SORCE and the CHASE Alliance. He will be one of the instructors of the Online Certificate of Health Economics and Outcomes Research that starts in the fall.

Ryan Hansen, PharmD, PhD Ryan Hansen has received a University of Washington K12 Mentored Career Development Award in Patient-Centered Out-comes Research and will be joining the Department of Pharmacy Faculty as an Acting Assistant Professor. During this two-year award period he will focus on gaining additional skills and theoretical knowledge on patient behaviors while executing several research projects.

Joshua Roth, PhD

Josh has accepted a position as the Kirchstein-NRSA Post-Doctoral Fellow at Group Health Research Institute in Seattle. He will also continue his work with Scott Ramsey at the Institute for Cancer Outcomes Research and Evaluation (ICORE), at Fred Hutchinson Cancer Research Center.

Jonathan Watanabe, PharmD, PhD Jon has accepted a position as Assistant Professor of Pharmacy at Western University College of Pharmacy, Pomona, CA. He will be involved with health and pharmaceutical policy analysis, epidemiology, outcomes research and long term care phar-macy practice.

Heidi Wirtz, PharmD, PhD Heidi was awarded the PhRMA Foundation 2-year post-doctoral health outcomes fellowship where she will pursue compara-tive effectiveness research in colorectal cancer upon completion of her PhD.

Postmenopausal Women: Results from the Women's

Health Initiative”. This research was accepted to a Paper

Session (oral podium presentation) at the 2012 American

Geriatrics Society (AGS) Annual Scientific Meeting. In

addition to being awarded the oral presentation at the AGS

meeting, her project was graded one of the top 50 student-

submitted abstracts for the 2012 annual meeting. As the

submitter of an abstract in this category, she received a

travel stipend from AGS to attend the conference.

Kai Yeung, MS, PharmD

Kai has completed his first year as a PhD student. During

this academic year, Kai explored his research interests

through a number of projects leading to 5 manuscripts in

various stages of publication. These projects, spanning

diverse subject matter including asthma, diabetes, lung

cancer, reimbursement agreements, renal transplantation,

and social values in decision making are united by his pri-

mary interest in the use of evidence and analytics to im-

prove healthcare decision making. Kai presented at the

2012 annual meeting of the Academy for Managed Care

Pharmacy in a presentation entitled, “Planning & Develop-

ment of an International Social Value Judgments Frame-

work.” Looking forward to his second year, Kai plans on

developing further mentored relationships and research

collaborations.

Current Students, cont.

6 PORPP

year. The most significant of these projects was: “Patient

perceptions of prophylaxis therapy in chronic and episodic

migraine,” which she presented in poster form at both the

American Academy of Neurology Annual Meeting and the

International Society for Pharmacoeconomics and Out-

comes Research Annual International Meeting. She also

worked on a preliminary cost-effectiveness model for a

new agent used for osteoarthritis of the knee. She looks

forward to continuing to learn more about outcomes re-

search during the upcoming year at Allergan.

Heidi Wirtz, MS, PharmD

Heidi successfully completed her General Exam in No-

vember 2011 and is currently conducting research on her

dissertation project titled, “Second Breast Cancer Events

in Relation to frequent Antibiotic Use: An Assessment of

Risk and the Development of a Framework to Evaluate

Detection Bias in Breast Cancer Pharmacoepidemiology

Studies”. Heidi is working with Denise Boudreau at the

Group Health Research Institute for her dissertation pro-

ject that emphasizes pharmacoepidemiology and methodo-

logical considerations in improving the design and inter-

pretation of real world, population-based research findings.

In addition to her dissertation work, Heidi is collaborating

with Shelly Gray, PharmD, MS, on a project titled,

“Anticholinergic Medication Use, Falls and Fracture in

A PhRMA Foundation Fellowship, focused on modeling

medication adherence in cost-effectiveness analysis ap-

plied in the primary prevention of cardiovascular dis-

ease. This summer, Julia spent two weeks at Pfizer in

New York establishing a research project and is delighted

to join the PORPP group.

Rahber Thariani, PhD

Rahber is about to enter the second year of his PhRMA

Foundation Health Outcomes Fellowship. He is working

on comparative effectiveness in genomic and proteomic

diagnostics and diagnostic-drug combinations alongside

David Veenstra and Scott Ramsey. Additionally, he is also

interested in how macro changes in the economic climate

influence the healthcare system. He has collaborated with

the UW Business School in projects involving technology

development, venture capital and entrepreneurship.

David van der Goes, PhD

Pfizer Post-Doctoral Fellow 2010-2012

David completed his time as the PORPP-Pfizer postdoc-

toral fellow this August. He is now a tenure-track profes-

sor of economics at the University of New Mexico. In ad-

dition to his appointment in the department of economics,

he is a Senior Fellow at the Robert Wood Johnson Founda-

tion Center for Health Policy and a professor in the Com-

bined BA/MD program. David has published papers in

Clinical Neurophysiology and the Journal of Military and

Veterans' Health (forthcoming). In addition, David was

part of a featured commentary published in Neurology.

Laura Gold, PhD

Laurie joined the Advancing Innovative Comparative Ef-

fectiveness research (ADVICE) project in January 2010

and is working on a study to determine whether the use of

MRI following diagnosis of breast cancer affects outcomes

such as mastectomy rates, cancer treatment patterns, and

costs related to breast cancer. For the ADVICE project,

she has published a paper outlining the history of regula-

tory approval and clinical uptake of breast imaging tech-

nologies and has another paper describing the patterns of

use of advanced breast imaging in progress. She also has

two papers in press from the Asthma Insights and Manage-

ment survey, which describe healthcare utilization and

costs of U.S. asthma patients with varying levels of disease

control. Laurie’s dissertation work in the Department of

Epidemiology at the UW focused on whether occupational

exposures to chlorinated solvents increased the incidence

of multiple myeloma. She also has performed research on

the epidemiology of cardiac arrests with the Emergency

Medical Services division of Seattle/King County Public

Health.

Julia Slejko, PhD

Julia recently joined the program as a PORPP-Pfizer post-

doctoral fellow. In May 2012, she completed her PhD at

the Center for Pharmaceutical Outcomes Research,

(CePOR) at the University of Colorado Skaggs School of

Pharmacy and Pharmaceutical Sciences where her advisor

was Jon Campbell, PhD. Her doctoral research, funded by

Post-Doctoral Fellows

2012 PORPP Retreat at Talaris Conference Center

Fall 2012 7

The winning paper for the 2011

PORPP Endowed Prize was writ-

ten by Veena Shankaran. The title

of her paper was: “Risk Factors for Financial Hard-

ship in Patients Receiving Adju-

vant Chemotherapy for Colon

Cancer: A Population-Based Ex-

ploratory Analysis”. The $1,000 Prize is awarded to

eligible candidates in the PhD or

Master’s program in PORPP, or related fields such as Pub-

lic Health Genetics, Health Services, Economics or Global

Health who are enrolled in a class taught by a PORPP fac-

ulty member. The paper must deal with an original health

policy or health economic issue.

PORPP Endowed Prize Recipient

Sean D. Sullivan, Director of the School’s Pharmaceutical Outcomes Research & Policy Program (PORPP), has

been named the Stergachis Family Endowed Professor and Director. The Stergachis Family Endowment was established in January 2012 and is named after Andy Stergachis, Profes-

sor of Epidemiology and Global Health and Adjunct Professor of Pharmacy and his wife, JoAnn Stergachis. Pro-fessor Stergachis was the founding director of PORPP and former Chair of the Department of Pharmacy. Andy

and JoAnn Stergachis made the lead individual gift to the directorship, which enhanced an already established

PORPP professorship award. Stergachis and Sullivan helped co-found PORPP in the School of Pharmacy in 1995. The two saw a need for a program that would strengthen research efforts and provide graduate-level

training in health outcomes and policy research. PORPP has become an internationally recognized center for pharmaceutical economics, drug safety, pharmaceutical policy research and graduate education.

As the Stergachis Family Endowed Director, Sullivan will have increased opportunities to strengthen PORPP’s significant impact. The endowment will provide him with additional administrative, research and training sup-

port. Further, it will help Sullivan and the faculty in the program to build on their legacy of inspiring students

and providing each PORPP student with specialized training in outcomes research. By Melinda Young

Sean Sullivan Becomes First PORPP Endowed Director

In April 2012, our esteemed col-

league, Dave Blough, left PORPP to

work for the U.S. Department of De-

fense. Dave joined our faculty in

1997 as our biostatistician in resi-

dence. For 15 years Dave was a close

colleague, and worked with many of

us on a multitude of research pro-

jects. On any given day, Dave would

conduct his own research on multiple

imputation or longitudinal methods,

collaborate on projects with faculty colleagues at UW or

the Fred Hutchinson Cancer Research Center, mentor

pharmacy and graduate students on statistical methods

Dave Blough Trades PORPP for Nuclear Subs

needed for their research, teach a Biostatistics class in the

core curriculum for the Doctor of Pharmacy students, and

attend the defense of a PhD student on whose committee

he served. Dave was a versatile biostatistician who could

easily work on projects across therapeutic areas, from lung

volume reduction surgery to prostate cancer, from alcohol

screening to risk factors for statin-associated rhabdo-

myolysis. Dave was funded on numerous grants and man-

aged to deliver on every one. His publication record of 100

manuscripts reflects his commitment to us all.

Dave’s reserved personality belied his considerable intel-

lect and expertise. He was both a mathematician and a

statistician by training, having earned Master’s degrees in

both, and a PhD in Statistics. He was elected to several

national scholastic honorary societies during his training.

At UW, in addition to his research with the School of

Pharmacy, Dave was a member of the Public Health Sci-

ences group at the Fred Hutchinson Cancer Research Cen-

ter, participated in projects with investigators at the VA,

and taught in UW Extension’s Clinical Trials Certificate

program. Earlier in his career, Dave served as a statistician

for both Washington State and Ohio State Universities,

Battelle Pacific Northwest National Laboratories, and with

the Department of Agricultural Economics at the Univer-

sity of Arizona. He served as a manuscript reviewer for

several biostatistics and economics journals and was active

in the American Statistical Association.

Setting off on what he called the final adventure of his

professional career, Dave, his lovely wife Terry, and their

beloved Irish Setter moved to upstate New York where

Dave is now a statistician with the US Department of De-

fense, employed in one of the nuclear submarine laborato-

ries. An avid hiker, Dave traded his summer trips to the

Sierra Nevada range of California for the Adirondack’s of

Northern New York. We wish Dave and Terry well and

miss Dave as a member of our group. We are actively

searching for a new biostatistician, but know that we will

never be able to fill Dave’s shoes.

8 PORPP

PORPP Creates Two New Certificate Programs

PORPP will launch two new certificate programs

this fall:

Certificate in Health Economics and

Outcomes Research This certificate is administered through the Profes-sional and Continuing Education Office. Admission is limited to 30 students per year, and this year’s quota has already been met. Students have enrolled from all over the world. Courses will be available on-line, and most of the core PORPP faculty are involved. More information can be found here: http://www.pce.uw.edu/certificates/health-economics.html

Graduate Certificate in Comparative

Effectiveness Research

Lou Garrison, as P.I. received a $250,000 grant from the PhRMA Foundation to start an interdisciplinary graduate certificate program in comparative effective-ness research at the UW. Beth Devine and Anirban Basu are Co-P.I.’s This certificate is open to current University of Washington graduate students. The grant also included funds for a Pre-Doctoral Fellowship and a Dissertation Award. The first recipient of the pre-doctoral fellowship is Maria Agapova, and the disser-tation award will go to John Dickerson, in Health Ser-vices. More information about this program can be found here: http://sop.washington.edu/porpp/certificate-programs/graduate-certificate-in-comparative-effectiveness-research.html

Fred Hutchinson Cancer Research Center has launched a new research insti-

tute – the first of its kind among comprehensive cancer centers nationwide –

dedicated to health economics and cancer outcomes research. The mission of

the Institute for Cancer Outcomes Research and Evaluation, or ICORE, is to

improve the efficiency and effectiveness of cancer prevention, early detection

and treatment to reduce the economic and human burdens of cancer.

Scott Ramsey, M.D., Ph.D., a national leader in health care economics, has

been appointed as the first director of ICORE, which is scheduled to begin

operations early next year.

“Cancer care in the United States is in crisis. Costs are rising at an unsustain-

able rate, putting tremendous strains on patients and the health care system,”

said Ramsey, a member of the Hutchison Center Public Health Sciences Divi-

sion. “The current environment in oncology health care delivery and policy

make this an ideal time to focus on health economics, comparative and cost-

effectiveness research, and health care policy,” he said, citing the 2011 Presi-

dent’s Cancer Panel report, which highlighted tremendous variations in can-

cer care nationwide. “A patient’s race, income, insurance, where they live,

and even what cancer doctor they first see can change their likelihood of re-

ceiving the best treatments and affect overall survival,” Ramsey said. “There

is a tremendous need to collect, analyze and provide evidence that supports

the provision of efficient, effective and cost-effective cancer care.”

Ramsey and colleagues envision the new institute to be both translational and

transformational, efficiently bringing scientific advances to the health care

sector, finding and implementing new models that maintain the quality of care

while reducing the financial burden of cancer for patients, health systems and

society.

Institute for Cancer Outcomes Research & Evaluation: ICORE

Fred Hutchinson Cancer Research Center

Student Publications

Maria Agapova

Lanteri MC, Kaidarova Z, Peterson T, Cate S, Custer B,

Wu S, Agapova M, Law JP, Bielawny T, Plummer F, To-

bler LH, Loeb M, Busch MP, Bramson J, Luo M, Norris

PJ. Association between HLA class I and class II alleles

and the outcome of West Nile virus infection: an explora-

tory study. PLoS One. 2011;6(8):e22948. PubMed PMID:

21829673; PubMed Central PMCID: PMC3148246.

Custer B, Agapova M, Bruhn R, Cusick R, Kamel H,

Tomasulo P, Biswas H, Tobler L, Lee TH, Caglioti S,

Busch M. Epidemiologic and laboratory findings from 3

years of testing United States blood donors for Trypano-

soma cruzi. Transfusion. 2012. PubMed PMID: 22339233.

Rafael Alfonso

Wong ES, Wang BC, Garrison LP, Alfonso-Cristancho

R, Flum DR, Arterburn DE, Sullivan SD. Examining the

BMI-mortality relationship using fractional polynomials.

BMC Med Res Methodol. 2011;11:175. PubMed PMID:

22204699; PubMed Central PMCID: PMC3273446.

Lin VW, Wright A, Flum DR, Garrison LP, Jr., Alfonso

-Cristancho R, Sullivan SD. Patients' experience and

outcomes after laparoscopic adjustable gastric banding in

Washington state. Surg Obes Relat Dis. 2012. PubMed

PMID: 22578289.

Wong ES, Wang BC, Alfonso-Cristancho R, Flum DR,

Sullivan SD, Garrison LP, Arterburn DE. BMI Trajecto-

ries Among the Severely Obese: Results From an Elec-

tronic Medical Record Population. Obesity (Silver Spring).

2012. PubMed PMID: 22314622.

Scott Ramsey, MD, PhD

Fall 2012 9

Carrie Bennette

Vickers AJ, Bennette C, Kibel AS, Black A, Izmirlian G,

Stephenson AJ, Bochner B.Who should be included in a

clinical trial of screening for bladder cancer?: A decision

analysis of data from the Prostate, Lung, Colorectal and

Ovarian Cancer Screening Trial. Cancer. 2012 Jun 26. doi:

10.1002/cncr.27692. [Epub ahead of print]

Poon SA, Silberstein JL, Savage C, Maschino AC,

Lowrance WT, Sandhu JS.Surgical practice patterns for

male urinary incontinence: analysis of case logs from certi-

fying American urologists.J Urol. 2012 Jul;188(1):205-10.

Vickers A, Bennette C, Steineck G, Adami HO, Johans-

son JE, Bill-Axelson A, Palmgren J, Garmo H, Holmberg

L. Individualized estimation of the benefit of radical

prostatectomy from the scandinavian prostate cancer group

randomized trial. Eur Urol. 2012 Aug;62(2):204-9. Epub

2012 Apr 19.

Katie Gries

Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmo-

chowski RR, Sullivan SD. Treatment Success for Overac-

tive Bladder with Urinary Urge Incontinence Refractory to

Oral Antimuscarinics: A Review of Published Evidence.

BMC Urology. 2009; 9(18)

Cara McDermott

McDermott CL, Sweet E, Tippens K, Hseih AA,

McCune JS. Advising Patients with Breast Cancer Re-

garding Aromatase Inhibitors ‐ Dietary Supplement Inter-

actions. Journal of Complementary and Alternative Medi-

cine. J Altern Complement Med. 2011 Nov;17(11):1043‐9.

McDermott CL, Gray SL. Cholinesterase Inhibitor Ad-

junctive Therapy for Cognitive Impairment and Depressive

Symptoms in Older Adults with Depression. Ann Pharma-

cother. 2012 Apr;46(4):599‐605. Epub 2012 Mar 13.

Ramsey SD, Holmes RS, McDermott CL, Blough DK,

Petrin KL, Poole EM, Ulrich CM. A Comparison of Ap-

proaches for Association Studies of Polymorphisms and

Colorectal Cancer Risk. Colorectal Dis. 2012 Mar 5. doi:

10.1111/j.1463‐1318.2012.03021.x. [Epub ahead of print]

Joshua Roth

Esmail L, Roth JA, Rangarao S, Deverka P, Ramsey SD,

Carlson JJ, Thariani R, Veenstra DL. Getting our pri-

orities straight: A qualitative study of stakeholders’ con-

siderations when prioritizing cancer genomics research.

Genetics in Medicine.

Carlson JJ, Thariani R, Roth JA, Gralow J, Henry NL,

Esmail L, Deverka P, Ramsey SD, Baker L, Veenstra DL.

Research Prioritization in Cancer Genomics: Formal Value

of Research Analyses within a Stakeholder-Informed Proc-

ess. Medical Decision Making.

Jonathan Watanabe

Sand PK, Rovner ES, Watanabe JH, Oefelein MG. Once-

daily trospium chloride 60 mg extended release in subjects

with overactive bladder syndrome who use multiple con-

comitant medications: Post hoc analysis of pooled data

from two randomized, placebo-controlled trials. Drugs

Laurie Gold, PhD

Gold LS, Klein G, Carr L, Kessler L, Sullivan SD. The

emergence of diagnostic imaging technologies in breast

cancer: discovery, regulatory approval, reimbursement,

and adoption in clinical guidelines. Cancer Imaging.

2012;12(1):13-24. PubMed PMID: 22275726.

Julia Slejko, PhD

Page RL, Slejko JF, Libby AM. A Citywide Smoking Ban

Reduced Maternal Smoking and Risk for Preterm Births:

A Colorado Natural Experiment. Journal of Women’s

Health. June 2012, 21(6):621-627.

Slejko JF, Libby AM, Nair KV, Valuck RJ, Campbell JD.

Pharmacoeconomics and Outcomes Research Degree-

Granting Programs in the United States. Research in Social

and Administrative Pharmacy. Available online 1 May

2012.

Sullivan PW, Ghushchyan VH, Slejko JF, Belozeroff V,

Globe DR, Lin S-L. The burden of adult asthma in the

United States: Evidence from the Medical Expenditure

Panel Survey. The Journal of allergy and clinical immu-

nology. 2011; 127(2):363-369.

Rahber Thariani, PhD

Thariani, R., Wong, W., Carlson, J.J., et al., Prioritiza-

tion in comparative effectiveness research: the CANCER-

GEN Experience. Med Care 2012; 50(5):388-93.

Thariani, R., Veenstra, D.L., Carlson, J.J., et al., Paying

for personalized care: cancer biomarkers and comparative

effectiveness. Mol Oncol 2012; 6(2):260-6.

David van der Goes, PhD

Ney JP, van der Goes DN, Nuwer M, Emerson R, Mina-

han R, Legatt A, Galloway G, Lopez J, Yamada T, Patel

AD, Ritzl EK, Skinner SA, Rippe D, Gronseth GS. Evi-

dence-based guideline update: Intraoperative spinal moni-

toring with somatosensory and transcranial electrical mo-

tor evoked potentials: Report of the Therapeutics and

Technology Assessment Subcommittee of the American

Academy of Neurology and the American Clinical Neuro-

physiology Society. Neurology. 2012 Jul 17;79(3):292-4.

PubMed PMID: 22802595.

Post-Doc Publications

Aging. 2011;28(2):151-60. PubMed PMID: 21275440.

Ney JP, van der Goes DN, Watanabe JH. Cost-

effectiveness of intraoperative neurophysiological moni-

toring for spinal surgeries: Beginning steps. Clin Neuro-

physiol. 2012;123(9):1705-7. PubMed PMID: 22386320.

Heidi Wirtz

Boudreau DM, Wirtz HS, Von Korff M, Catz SL, St.

John J, Stang PE. A survey of adult awareness and use of

medicine containing acetaminophen. 2012. In press at

Pharmacoepidemiol Drug Saf.

Kai Yeung

Yeung K. Using AHRQ's evidence-based reports to im-

prove managed care pharmacy practice: oral antidiabetic

agents. J Manag Care Pharm. 2011;17(8):641-9. PubMed

PMID: 21942305.

Student Publications, cont.

10 PORPP

Faculty Recent Publications

Ney JP, van der Goes DN, Watanabe JH. Cost- effec-

tiveness of intraoperative neurophysiological monitoring

for spinal surgeries: Beginning steps. Clin Neurophysiol.

2012 Sep;123(9):1705-7. Epub 2012 Mar 3. PubMed

PMID: 22386320.

Anirban Basu

Basu A, Kee RA, Buchanan D, Sadowski LS. Compara-

tive cost analysis of housing and case management pro-

gram for chronically ill homeless adults compared to usual

care. Health Services Research 2012; 47(1pt2): 523-543.

Basu A, Meltzer D. Private manufacturers’ thresholds to

invest in comparative effectiveness trials. Pharma-

coEconomics In Press.

Basu A. Person-Centered Treatment (PeT) effects using

instrumental variables. 2012 National Bureau of Economic

Research Working Paper No w18056.

Joseph Babigumira

Babigumira J, Stergachis A, Veenstra DL, Gardner JS,

Ngonzi J, Mukasa-Kivunike P, Garrison LP. Estimating

the Costs of Induced Abortion in Uganda: A Model-Based

Analysis. BMC Public Health 2011, 11:904

doi:10.1186/1471-2458-11-904.

Babigumira J, Veenstra DL, Gardner JS, Stergachis A,

Garrison LP. Potential Cost-Effectiveness of Universal

Access to Modern Contraceptives in Uganda. PLoS

ONE. 2012;7(2):e30735. Epub 2012 Feb 17.

Denise Boudreau

Boudreau DM, Wirtz H, Von Korff M, Catz SL, St. John

J, Stang PE. A survey of patient awareness and use of

medicine containing acetaminophen. In press at Pharma-

coepidemiol Drug Saf.

Cutrona SL, Toh S, Iyer A, Foy S, Daniel G, Nair V, Ng

D, Butler M, Nakasato C, Boudreau D, Andrade S, For-

row S, Goldberg R, Gore J, McManus D, Racoosin JA,

Gurwitz, JH. Validation of acute myocardial infarction in

the Food and Drug Administration’s Mini-Sentinel pro-

gram. In press at Pharmacoepidemiol Drug Saf.

Aiello Bowles EJ, Boudreau DM, Chubak J, Yu O, Fujii

M, Chestnut J, Buist DSM. Patient-reported side effects

and discontinuation of endocrine therapy among women

with early stage breast cancer. In press at J Oncol Pract

2012.

Brian Bresnahan

Branch, KR, Bresnahan, BW, Veenstra, DL, Shuman,

WP, Weintrabu, WS, Busey, JM, Elliott DJ, Mitsumori,

LM, Strote, J, Jobe, K, Dubinsky, T, Caldwell, J. Eco-

nomic outcome of cardiac CT-based evaluation of stan-

dard of care for suspected acute coronary syndrome in the

emergency department: a decision analytic model, Aca-

demic Radiology, 2012; 19:265-273.

Otero, HJ, Chamber, HD, Bresnahan, BW, Kamae, MS,

Yucel, EK, and Neumann, PJ. Medicare’s national

coverage determinations in diagnostic radiology: examin-

ing evidence and setting limits, submitted to Academic

Radiology, in press 2012.

Friedly, JL, Bresnahan, BW, Comstock, B, Turner, JA,

Deyo, RA, Sullivan, SD, Heagerty, P, Bauer, Z,

Nedeljkovic, SS, Avins, AL, Nerenz, D, Jarvik, JG. Study

Protocol- Lumbar Epidural Steroid Injections for Spinal

Stenosis (LESS): a double-blind randomized controlled

trial of epidural steroid injections for lumbar spinal steno-

sis among older adults, submitted to BioMed Central Mus-

culoskeletal Disorders, 2012, 13:48.

Josh Carlson

Roth JA, Carlson JJ. The Prognostic Role of ERCC1 in

Advanced Non-Small Cell Lung Cancer: A Systematic

Review & Meta-Analysis. Clinical Lung Cancer. 2011.

Roth JA, Carlson JJ. Cost-Effectiveness of Gemcit-

abine+Cisplatin vs. Gemcitabine Monotherapy in Ad-

vanced Biliary Tract Cancer. Journal of Gastrointestinal

Cancer. 2011.

Carlson JJ, Wong WB, Reyes C, Veenstra DL. Budget

Impact of Erlotinib for Maintenance Therapy in Advanced

Non-Small Cell Lung Cancer. Journal of Medical Eco-

nomics Vol. 14, No. 2, 2011, 159-16.

Beth Devine

Lin VW, Ringold S, Devine EB. Comparison of ustekinu-

mab with other biologic agents for treatment of moderate-

to-severe psoriasis: A Bayesian network meta-analysis. (in

press at Arch Dermatol, May 2012)

Overby CL, Devine EB, Tarczy-Hornoch P, Kalet. Deriv-

ing Rules and Assertions From Pharmacogenomic Knowl-

edge Resources In Support Of Patient Drug Exposure Pre-

dictions. J Am Med Inform Assoc. 2012 Apr 26. [Epub

ahead of print]

Gillard, Patrick, Devine EB, Varon S, Maglinte GA, Han-

sen RN, Sullivan SD. Mapping from disease-specific

measures to health-state utility values in migraineurs.

Value Health. 2012 May;15(3):485-94. [Epub 2012 Feb 9]

Louis Garrison, Jr.

Bergenstal RM, Garrison LP, Miller LA, Hou L, Blick-

ensderfer A, Zagar A, Stanley S, Bhargava A, Wade R,

Herman WH. Exenatide BID Observational Study (ExOS):

results for primary and secondary endpoints of a prospec-

tive research study to evaluate the clinical effectiveness of

exenatide BID use in patients with type 2 diabetes in a real

-world setting. Curr Med Res Opin. 2011 Dec;27(12):2335

-42.

Best JH, Lavillotti K, Deyoung MB, Garrison LP. The

effects of exenatide BID on metabolic control, medication

use, and hospitalization in patients with type 2 diabetes

mellitus in clinical practice: a systematic review. Diabetes

Obes Metab. 2011 Nov 10.

Casciano R, Chulikavit M, Di Lorenzo G, Liu Z, Baladi

JF, Wang X, Robertson J, Garrison L. Economic evalua-

tion of everolimus versus sorafenib for the treatment of

metastatic renal cell carcinoma after failure of first-line

sunitinib. Value Health. 2011 Sep-Oct;14(6):846-51.

Bernardo Goulart

Goulart, BHL; Bensink, ME; Mummy, DG; Ramsey, SD.

Lung Cancer Screening with Low‐Dose Computed Tomo-

graphy: Costs, National Expenditures, and Cost‐

Fall 2012 11

Effectiveness. Journal of the National Comprehensive

Cancer Network. 2012;10:267‐275.

Cheng, MM.; Goulart, B.; Veenstra DL; Blough, DK;

Devine, EB. A Network Meta‐analysis of Therapies for

Previously Untreated Chronic Lymphocytic Leukemia.

Cancer Treatment Reviews. March 2012 (E‐pub).

Goulart, B. Economic Considerations in Lung Cancer

Screening with Low‐Dose Computed Tomography.

American Society of Clinical Oncology Educational Book.

2012.

Shelly Gray

Lakey SL, LaCroix AZ, Gray SL, Borson S, Williams

CD, Calhoun D, Goveas JS, Smoller JW, Ockene JK, Ma-

saki KJ, Coday MC, Rosal MC, Woods NF. Antidepres-

sant use, Depressive Symptoms, and Incident Frailty in

Women Aged 65 and Older from the Women’s Health

Initiative Observational Study. J Am Geriatr Soc

2012;60:854‐61

McDermott C, Gray SL. Cholinesterase inhibitor adjunc-

tive therapy for cognitive impairment and depressive

symptoms in older adults with depression. Ann Pharmaco-

ther 2012;46:599‐605

Peron EP, Gray SL, Hanlon JT. Medication use and func-

tional status decline in older adults: A narrative review.

Am J Geriatr Pharmacother 2011;9:378‐91.

Tom Hazlet

Garrison LP Jr, Bauch CT, Bresnahan BW, Hazlet TK,

Kadiyala S, Veenstra DL. Using cost‐effectiveness analy-

sis to support research and development portfolio prioriti-

zation for product innovations in measles vaccination. J

Infect Dis. 2011 Jul;204 Suppl 1:S124‐32.

Jerry Jarvik

Friedly JL, Bresnahan BW, Comstock B, Turner JA,

Deyo RA, Sullivan SD, Heagerty P, Bauer Z, Nedeljkovic

SS, Avins AL, Nerenz D, Jarvik JG. Study Protocol –

Lumbar Epidural Sterioid Injections for Spinal Stenosis

(LESS): a double-blind randomized controlled trial of

epidural steroid injections for lumbar spinal stenosis

among older adults. BMC Musculoskeletal Disorders Mar

29 2012:13:48

Jarvik JG, Comstock BA, Bresnahan BW, Nedeljkovic

SS, Nerenz DR, Bauer A, Avins AL, James K, Turner, JA,

Heagerty P, Kessler L, Friedly JL, Sullivan SD, Deyo

RA. Study Protocol: The Back pain Outcomes using Lon-

gitudinal Data (BOLD) Registry. BMC Musculoskeletal

Disorders, May 3 2012;13(1):64.

Roudsari B, Psoter KJ, Fine GC, Jarvik JG. Falls, Older

Adults and the Trend in Utilization of CT in a Level I

Trauma Center. American Journal of Roentgenology, May

2012; 198(5):985-991.

Larry Kessler

Zeliadt SB, Hoffman RM, Etzioni R, Gore JL, Kessler

LG, Lin DW. (2011) Influence of publication of US and

European prostate cancer screening trials on PSA testing

practices. J Natl Cancer Inst. Mar 16; 103(6): 520-3. Epub

2011 Feb 28.

Mankoff, DA, Specht, JM, Eubank, WB, Kessler, LG.

(2012) Fluerodeoxyglucose Positron Emission Tomogra-

phy-Computed Tomography in Breast Cancer: When…and

When Not? Journal of Clinical Oncology February 2012,

CO.2011.40.6975.

Jarvik, JG, Comstock, BA, Bresnahan, BW,

Nedeljkovic, SS, Nerenz, DR, Bauer, Z, Avins, AL, James,

K, Turner, JA, Heagerty, P, Kessler, LG, Friedly JL, Sul-

livan, SD, Deyo, RA. (2012) Study Protocol: The Back

pain Outcomes using Longitudinal Data (BOLD) Registry.

BMC Medicine 2012 May 3, 13:64.

Scott Ramsey

Goulart, BHL; Bensink, ME; Mummy, DG; Ramsey, SD.

Lung Cancer Screening with Low‐Dose Computed Tomo-

graphy: Costs, National Expenditures, and Cost‐Effectiveness. Journal of the National Comprehensive

Cancer Network. 2012;10:267‐275.

Ramsey SD, Holmes RS, McDermott CL, Blough DK,

Petrin KL, Poole EM, Ulrich CM. A Comparison of Ap-

proaches for Association Studies of Polymorphisms and

Colorectal Cancer Risk. Colorectal Dis. 2012 Mar 5. doi:

10.1111/j.1463‐1318.2012.03021.x. [Epub ahead of print]

Carlson JJ, Thariani R, Roth JA, Gralow J, Henry NL,

Esmail L, Deverka P, Ramsey SD, Baker L, Veenstra DL.

Research Prioritization in Cancer Genomics: Formal Value

of Research Analyses within a Stakeholder-Informed Proc-

ess. Medical Decision Making.

Andy Stergachis

Corbell C, Katjitae I, Sagwa E, Mabirizi D, Nwokike J,

Mengistu A, Lates J, Fuller S, Stergachis A. Records

linkage of electronic data bases for the assessment of ad-

verse effects of antiretroviral therapy in Namibia. Pharma-

coepi Drug Safety. 2011 Oct 19. doi: 10.1002/pds.2252.

Lavonas EJ, Fries JF, Furst DE, Rothman KJ, Stergachis

A, Vaida AJ, Zelterman D, Reynolds KM, Green JL, Dart

RC. Comparative risks of non-prescription analgesics: a

structured topic review and research priorities. Exp Opin

Drug Safety, 2012; 11(1):33-44.

Sangaré L,Weiss NS, Brentlinger PE, Richardson BA,

Staedke SG, Kiwuwa MS, Stergachis A. Determinants of

use of insecticide treated nets for the prevention of malaria

in pregnancy: Jinja, Uganda PLoS ONE June 2012, Vol-

ume 7, Issue 6, e39712.

Sean Sullivan

Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost‐effectiveness of general population screening for hepatitis

C virus in the United States. Clinical Infectious Disease

2012 May;54(9):1259‐71.

Gillard P, Devine EB, Varon S, Liu L, Sullivan SD. Map-

ping from disease‐specific measures to health‐state utility

values in individuals with migraine. Value in Health 2012

May;15(3):485‐94.

Wong E, Wang BCM, Garrison LP, Alfonso RC, Flum

D, Arteburn D, Sullivan SD.Body mass index trajectories

among the severely obese: results from an electronic medi-

cal records population. In press Obesity

Faculty Recent Publications, cont.

12 PORPP

Anirban Basu

PI, Empowering the Annual Health Econometrics

Workshop, AHRQ, 01/2012-12/2013

Co-PI, Innovative Methods for Modeling Longitudinal

Medical Costs, AHRQ, 01/2012-08/2016

Co-PI, Comparative Effectiveness of Dynamic Patterns

of Glucose Lowering Therapies, AHRQ, 07/2012-

06/2016

Denise Boudreau

PI, Commonly Used Medications and Breast Cancer

Recurrence, National Cancer Institute 9/1/2007-7/31/2012

Co-investigator. Cardiovascular Research Network Sur-

veillance - ARRA. National Heart, Lung, and Blood Insti-

tute, 2009-2012.

Co-Inv. Pharmacogenetics in Rural and Underserved

Populations. National Institute of General Medical Sci-

ences. 2010-2015.

Co-Inv. FDA Sentinel-Infrastructure. Food and Drug

Administration.

Consultant. Statins and Lymphoma Malignancy Risk

in a Large Multi-Site Population Based Cohort. NCI.

2010-2014.

Brian Bresnahan

Co-Inv. Resource Over-Utilization Due to Serious Alco-

hol Related Injuries, National Inst. of Health, 2010-2012.

Co-Inv. Back pain Outcomes using Longitudinal Data,

AHRQ CHOICE award, 2010 - 2013.

PI, Developing web‐based learning modules for radiol-

ogy in health services research, comparative effective-

ness research, and health economic evaluation, Ra-

diologic Society of North America (RSNA) Education

Grant

Faculty — Recent Grants

David Veenstra

Goddard KA, Knaus WA, Whitlock E, Lyman GH, Feigel-

son HS, Schully SD, Ramsey S, Tunis S, Freedman AN,

Khoury MJ, Veenstra DL. Building the evidence base for

decision making in cancer genomic medicine using com-

parative effectiveness research. Genet Med. 2012 Apr 19.

doi:10.1038/gim.2012.16. [Epub ahead of print] PMID:

22516979.

Guzauskas GF, Hughes DA, Bradley SM, and Veenstra

DL. A Risk–Benefit Assessment of Prasugrel, Clopido-

grel, and Genotype-Guided Therapy in Patients Undergo-

ing Percutaneous Coronary Intervention. Clin Pharmacol

Ther, 2012 May;91(5):829-37. doi: 10.1038/clpt.2011.303.

Epub 2012 Mar 28. PMID: 22453194.

Guzauskas GF, Boudreau DM, Villa KF, Levine SR,

Veenstra DL.The Cost-Effectiveness of Primary

Stroke Centers for Acute Stroke Care. Stroke. 2012 Jun;43

(6):1617-23. PMID: 22535277

Beth Devine

PI, UW-Allergan Post-Doctoral Fellowship for

PharmDs, Allergan Pharmaceuticals, 07/12-06/14

Co-Inv. ( PI: Garrison), Developing a Center of

Excellence for a Comparative Effectiveness Research

Education Program at UW, PhRMA Foundation, 12/11-

11/14

Co-Inv. (PI: Flum), Surgical Care and Outcomes As-

sessment Program Comparative Effectiveness Research

Network (SCOAP-CERTN). AHRQ R01 (2010-2013)

Co-Inv. (PI: Gallagher), Communication to Prevent and

Respond to Medical Injuries: WA State Collaborative.

AHRQ R18 (2010-2013)

Louis Garrison

Principal Mentor, UW-Pfizer Post-Doctoral Fellow-

ship, 2012-2014.

PI, Developing a Center of Excellence for a Compara-

tive Effectiveness Research Education Program at UW,

PhRMA Foundation, 12/11-11/14

PI, South African Training for Trainers Workshop and

Follow-up, USAID to Management Sciences for Health,

2012-2013

Bernardo Goulart

Co-PI, SEER‐Medicare study of physician‐related fac-

tors and patterns of referral for chemotherapy in ad-

vanced non‐small‐cell lung cancer, Genentech

PI, Assessing Outcomes & Costs of Low-Dose Com-

puted Tomography Lung Cancer Screening in Real-

World Practice: A Pilot Study, FHCRC Public Health

Sciences Bid & Proposal Project

Co-PI, Outcomes and Costs of Low‐Dose Computed

Tomography for Early Detection of Lung Cancer: a

Pilot Registry Study, Gregory Fund award

Shelly Gray

Co-Inv. Alzheimer’s Disease Patient Registry, 2009-

2013, NIA

PI (UW subcontract, Larson PI), Longitudinal Effect of

Anticholinergic Polypharmacy on dementia and neuro-

pathology 3/1/12‐8/31/14

Scott Ramsey

PI, A Study of Cancer Diagnosis as a Risk Factor for

Personal Bankruptcy, in response to NCI Challenge

Grant RFA

PI, Center for Comparative Effectiveness Research in

Cancer Genomics - CANCERGEN NCI “GO” grant

RFA

Co-Inv. ADVancing Innovative Comparative Effective-

ness research-cancer diagnostics ADVICE NCI “GO”

grant RFA

PI, A Multi-State Study of Cancer Treatment and Out-

comes Among American Indians, NCI

PI, A Retrospective Evaluation of Patterns of Care for

American Indian and Alaska Native Men with Eleva-

teed Prostate Specific Antigen, sub-award from Univer-

sity of Washington, CDC

Fall 2012 13

14 PORPP

PI, Luxembourg: Project Lung Cancer, Piper and Flynn

Foundations, Translational Genomics Research Institute

Andy Stergachis

PI, (UW Component); Systems for Improved Access to

Pharmaceuticals and Services (SIAPS), USAID to Man-

agement Sciences for Health (MSH) 2011-2014

PI, Assessment of the Safety of Antimalarial Drug Use

During Early Pregnancy. 2010-13. Malaria in Pregnancy

Consortium via the Bill and Melinda Gates Foundation.

PI, Global Medicines Program. 2010-13. Department of

Global Health, UW.

Sean Sullivan

PI, CHASE K12 Training, 2010-2013, AHRQ

Co‐Inv. From Evidence‐Base to Practice: Implementing

RDAD in AAA Community‐Based Services. (National

Institute of Aging, Linda Teri, PhD ‐ PI)

PI, K‐12 Mentored Career Development Program in

Patient‐Centered Outcomes Research (AHRQ) July

2012 to June 2014.

Co‐Director, Pacific Northwest Evidence‐Based Prac-

tice Center (AHRQ) August 2012 to July 2017

David Veenstra

PI, Risk-Benefit Framework for Genetic Tests, 2009-

2012, CDC

PI, Center for Cancer Genomic Evaluations of Com-

parative Effectiveness (CANCERGEN), 2009-2012,

NCI

Co-Inv. Center for Genomics and Health care Equality,

2010-2015, NIH/NGRI

Co-Inv. Pharmacogenetics in Rural and Underserved

Populations, 2010-2015, NIGMS

PORPP would like to acknowledge our many sup-

porters of this past year. Our accomplishments

would not have been possible without these gener-ous educational grants and gifts.

Allergan

Bayer AG

Jon & Chris Campbell

Josh Carlson, PhD

Catherine Corbell, PhD

Beth Devine, PharmD, MBA, PhD

Quy and Van Thu Dinh

Eli Lilly & Company

Louis and Fran Garrison, Jr.

GE Foundation

Genentech, Inc.

Thomas Hazlet, PharmD, DrPH

Mitchell and Mandy Higashi

Nina Hill, PhD

ISPOR

Douglas Kligman & Sarah Ahmann

MLA Services

Sarika Ogale, PhD & Sumit Mahajan, PhD

Shelby and Steve Reed

Eldon Spackman, PhD

Andy and Joanne Stergachis

Scott Strassels, PhD

Strategic North

Donna Sullivan, MS

Sean and Catrena Sullivan

UBC Health Care Anayltics, Inc.

David and Julie Veenstra

Dr. Hwee L. Wee

William Wong, PharmD, MS

PORPP Health Technology Fund (Eli Lilly,

GE Healthcare, Genentech, GlaxoSmith-Kline, Novartis, Ortho-McNeil, Pfizer, Roche, Sanofi-Aventis)

Gifts